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Abstract
Objective: The aim of this study is to develop a nomogram for prediction of pathologic complete remission
(pCR) after preoperative chemoradiotherapy (CRT) for rectal cancer.
Methods: mRNA expression levels of seven molecular markers [p53, p21, Ki-67, vascular endothelial growth
factor (VEGF), CD133, CD24, CD44] were measured by reverse transcriptase polymerase chain reaction (RT-
PCR) in 120 rectal cancers. Endoscopic findings of clinical complete remission (cCR) and biologic variables were
used to construct nomogram in the training group (n=80), which was validated in the validation group (n=40).
Results: mRNA expression levels of four markers (p53, p21, Ki67, CD133) correlated with pCR (24/80, 30.0%)
in the training group. Low expression of p53 and/or high expression of p21, Ki67 and CD133 showed greater pCR
rate. pCR was shown in 18 (69.2%) of 26 cases showing endoscopic cCR in the training group. Higher pCR rate
was demonstrated in lower tumor location than middle tumor (19/49, 38.8% vs. 5/31, 16.1%). A nomogram for
prediction of pCR was developed from the multivariate prediction model using these six variables, which showed
good discrimination ability  in the training group [area under the curve (AUC)=0.945] and validation group
(AUC=0.922). The calibration plot showed good agreement between actual and predicted pCR in both patient
groups.
Conclusions: Nomogram for assessment of pCR can be useful for making treatment decisions after CRT
according to predicted responses.
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Introduction
Most expert groups and treatment guidelines have adopted
preoperative chemoradiotherapy (CRT) as the preferred
method  to  improve  oncologic  outcomes  and  allow
performance  of  sphincter-preserving  surgery  through
tumor downstaging in patients with advanced middle or
low  rectal  cancer  (1).  The  ideal  outcome  of  CRT  is
complete response, in which the tumor is totally replaced
by scar. The rate of pathologic complete remission (pCR)
after  preoperative  CRT  ranges  from  12%  to  16%  for
standard CRT (2,3) and can increase to 24%−30% with
advanced regimens and targeted chemotherapy agents (4,5).
Patients with significant response to CRT are expected to
show  better  oncologic  outcomes,  and  those  with  pCR
potentially might even avoid major surgery (6,7).
  Original Article
© Chinese Journal of Cancer Research. All rights reserved. www.cjcrcn.org Chin J Cancer Res 2020;32(2):228-241
To date, a number of tumor proteins are being studied as
candidate predictive markers for prediction of response to
CRT in rectal cancer. These proteins can be easily assessed
by  immunohistochemical  (IHC)  analysis  or  reverse
transcriptase  polymerase  chain  reaction  (RT-PCR).  In
previous study, we demonstrated a scoring system based on
IHC analysis of four tumor proteins (p53, VEGF, p21 and
Ki67)  that  accurately predicted pCR in middle and low
rectal  cancer  (8).  Furthermore,  we  validated  the
significance  of  these  biomarkers  and  provide  more
quantitative data by RT-PCR for comprehensive analysis of
potential predictive markers (9).
It  has  also been suggested that  endoscopic finding of
gross tumor after preoperative CRT can be used as a tool
for evaluation of tumor response, and this is supported by
some studies with favorable outcomes (10,11).
Each  modality  is  not  enough  as  a  predictive  tool
individually;  therefore,  an  integrated  use  of  various
evaluation tools might provide comprehensive information
about CRT response and yield better predictive outcomes.
The combination of gross tumor finding and numerous
potential  molecular  markers  should  provide  a  good
predictive model for individualized treatment strategy.
This study aimed to develop a nomogram for prediction
of pCR after preoperative CRT in rectal cancer based on
mRNA expression of molecular markers measured by RT-
PCR and endoscopic findings.
Materials and methods
Patients
A total of 120 consecutive patients with rectal cancer were
enrolled prospectively between May 2016 and April 2019.
The inclusion criteria were histologically proven primary
rectal adenocarcinoma clinically staged as T2N(+)M0 or
T3−4NanyM0  and  planned  for  preoperative  CRT  and
curative resection.
Eighty patients were designated to the training group for
development  of  the  nomogram  in  serial  order  for
prediction  of  pCR.  For  external  validation  of  the
nomogram, consecutive 40 patients were designated to the
validation group in sequence of treatment time.
All patients underwent preoperative staging (clinical T-
and  N-staging)  by  magnetic  resonance  imaging  (MRI).
Clinical N(+) stage was defined as the presence of regional
lymph nodes larger than 10 mm or with spiculated shape.
Single experienced gastrointestinal radiologists reviewed all
of  the  MRI  studies  and  calculated  the  tumor  volume.
During  this  process,  the  tumor  margin  was  manually
traced, and the summation of each crosssectional image was
processed  on  a  workstation  using  imaging  software
(Aquarius workstation; TeraRecon, San Mateo, USA). The
radiologists were blinded to clinical data and permanent
pathologic results.
After inclusion and before starting preoperative CRT, all
patients underwent rigid sigmoidoscopy and two-punch
biopsy from the visibly deepest area of the tumor, which
was preserved in frozen status and further used for RT-
PCR analysis. Low and middle rectal cancers were defined
as  lower  tumor  edge  located  <5  cm  and  5−10  cm,
respectively, from the anal verge by rigid sigmoidoscopy.
Endoscopy was performed before preoperative CRT and
4 weeks after completion of preoperative CRT. We defined
the endoscopic findings of tumor after preoperative CRT
and evaluated the treatment response.
This  study was  approved by  the  Institutional  Review
Board (IRB) for the protection of human subjects.
Preoperative CRT and surgery
All  patients  completed  preoperative  CRT  in  full  and
underwent curative surgery at 8 weeks after completion of
CRT.
Radiation therapy was delivered using dual-photon linear
accelerators  at  an energy level  of  6-MV/10-MV. Long-
course radiation therapy included 25 fractions of 1.8 Gy
each delivered to the pelvis over a period of 5 weeks (5 d
per  week),  resulting  in  a  total  radiation  dose  of  45  Gy,
followed by a 5.4-Gy boost targeting the primary tumor.
Chemotherapy was administered to all patients with two
types of regimen: 5-fluorouracil with leucovorin or xeloda
only.  Two  cycles  of  intravenous  bolus  injection  of  5-
fluorouracil (425 mg/m2/d) and leucovorin (20 mg/m2/d)
were administered for 5 d during the first and fifth weeks of
radiation therapy. Xeloda was continuously administered
orally at a dose of 1,450 mg/m2/d twice daily during the
radiation therapy period.
Quantitative real-time PCR
Tissue samples which have tumor content more than 90%
were  analyzed.  Total  RNA  was  isolated  from  frozen
samples and used for RT-PCR. We extracted total RNA
with an RNeasy  plus  mini  kit  (Qiagen,  Valencia,  USA)
according to the manufacturer’s instructions. cDNA was
synthesized  using  a  Transcriptor  first-strand  cDNA
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synthesis kit (TaKaRa Bio Inc., Otsu, Japan) and 1 μg of
total  RNA.  We conducted  real-time  PCR in  duplicate
using TaqMan master  mix  (Applied  Biosystems,  Foster
City, USA) and the Applied Biosystems ViiA7 Real-Time
PCR System. Seven biomarkers (P53, P21, Ki67, VEGF,
CD133, CD24, CD44) were chosen as candidates from our
previous  research  findings  (8)  and  published  data,  and
mRNA  expression  levels  were  investigated.  mRNA
expression  levels  of  TP53  (assay  ID  Hs01034249_m1),
CDKN1A  (assay  ID Hs00355782_m1),  MKI67  (assay  ID
Hs01032443_m1),  vascular  endothelial  growth factor  A
(VEGFA)  (assay ID Hs00900055_m1), PROM1  (assay ID
Hs01009250_m1), CD44 (assay ID Hs01075861_m1) and
CD24 (assay ID Hs03044178_g1) were normalized to that
of  the  glyceraldehyde-3-phosphate  dehydrogenase
(GAPDH) housekeeping gene (assay ID Hs02758991_g1).
We  performed  relative  quantif ication  using  the
QuantStudio  software  v1.2  (Applied  Biosystems,
ThermoFisher Scientific, USA). Expression level of each
mRNA was indicated by ΔCt compared to expression of
GAPDH (ΔCt = target Ct – GAPDH Ct). The quantity of
mRNA in pCR tissue relative to that in non-pCR tissue was
calculated from the relative ratios of 2−ΔCt between the two
conditions.  Lower ΔCt and higher 2−ΔCt  values indicate
higher expression of each mRNA.
Endoscopic findings
Endoscopic gross tumor findings after preoperative CRT
were classified according to morphologic characteristics.
No visualization of  tumor,  white  scar,  or  red scar  were
defined  as  clinical  complete  remission  (cCR),  whereas
ulcerations and remaining masses of any size were defined
as  non-cCR  (Figure  1).  The  endoscopic  findings  were
interpreted by two independent endoscopists  who were
blinded  to  the  patients’  clinical  information.  The
consistency of the endoscopic findings between the two
independent observers was greater than 90%. In cases of
disagreement, the endoscopic finding was determined by
consensus.
Assessment of tumor response to CRT and histopathology
A single pathologist reviewed all of the surgical specimens.
The 7th American Joint  Committee on Cancer (AJCC)
TNM  staging  manual  was  used.  T-downstaging  was
observed if pathologic T-stage (pT) was lower than clinical
T-stage (cT) in the same patient. In patients who initially
presented with clinically positive lymph nodes [cN(+)], N-
downstaging  was  defined  as  conversion  to  pathological
lymph node negative status [pN(−)]. The tumor response to
preoperative  CRT  was  evaluated  using  the  Mandard’s
tumor regression grade (TRG) (12). Tumors classified as
TRG  1  or  TRG  2  were  considered  to  be  responders,
whereas tumors staged as TRG 3−5 were defined as non-
responders. pCR was defined as no viable tumor (TRG 1)
with no lymph node involvement (pN0).
Statistical analysis
Fisher’s  exact  or  χ2  tests  were  used for  categorical  data
analysis. Two-sided t-test or Mann-Whitney test was used
for continuous variables. The significance between each
variable and pCR was analyzed using univariate logistic
regression analysis  and selected variables  were used for
subsequent multivariate logistic regression analysis. The
final  multivariate  model  was  developed  for  the  pCR
prediction  model  and  tested  by  Hosmer-Lemeshow
goodness of fit test for evaluation of prediction ability. A
nomogram for prediction of pCR was developed using the
multivariate  model  with  predictive  variables.  The
discrimination and calibration performance were quantified
 
Figure 1  Various endoscopic findings of primary tumors after
preoperative chemoradiotherapy. (A) No tumor visualization; (B)
white scar; (C) red scar; (D) ulceration; (E) remaining mass.
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for evaluation of the mode performance. Discrimination is
the predictor’s ability to distinguish between pCR and non-
pCR.  Discrimination  ability  was  measured  by  the  area
under a receiver operating characteristic (ROC) curve; a
higher ROC area under the curve (AUC) means a better
discriminatory power. An AUC of 0.50 means that the test
is as good as random chance for discriminating an outcome,
whereas an AUC of 1.0 means perfect discrimination of the
rest (sensitivity and specificity of 100%). In general, the
model is considered relatively good for values greater than
0.75.  Calibration  is  the  agreement  between  actual
probability and predicted probability of pCR produced by
the model.  This  was  evaluated with a  calibration curve,
where patients were grouped by predicted pCR and then
plotted  as  actual  versus  predicted  pCR.  We  used  the
bootstrapping  resampling  method  (300  repetitions)  to
obtain relatively unbiased estimates and to assess internal
validation.  Both  discrimination  and  calibration  were
evaluated  in  the  training  and  the  validation  set.  All
statistical  analyses  were  performed  using  IBM  SPSS
statistics (Version 20; IBM Corp., New York, USA) and R
software  version  3.0.1  (the  R  foundation  for  statistical
computing,  Vienna,  Austria).  Values  of  P<0.05  were
considered statistically significant.
Results
Patient characteristics and clinical variables
A total of 120 consecutive patients were included in this
study. Detailed patient characteristics for the training and
validation  sets  are  listed  in  Table  1.  Before  starting
treatment,  the  majority  of  patients  in  the  training  set
presented with advanced T-stage and N-stage:  cT3−T4
stage  was  diagnosed  in  97.5%  and  cN(+)  in  81.2%  of
patients (Table 1).
In the training set, good response to preoperative CRT
(TRG 1 and TRG 2) was observed in 50.0% of patients,
and pCR was revealed in 30.0% of patients. The clinical
and pathologic characteristics of patients in the validation
set and training set were similar (Table 1).
Univariate analysis of different clinical variables in the
training  set  revealed  that  tumor  location  in  the  lower
rectum was significantly associated with pCR and TRG
response.  Tumors  located  in  the  lower  rectum
demonstrated significantly higher rates of pCR and TRG
1−2 than middle rectal tumors (Table 2).
Endoscopic findings and correlation with pCR
Endoscopic findings demonstrated a significant correlation
between cCR and pCR or TRG 1−2 in the training set.
pCR  was  shown  in  18  (69.2%)  of  26  cases  defined  as
endoscopic cCR. Non-pCR was shown in 48 (88.9%) of 54
cases defined as endoscopic non-cCR. Endoscopic findings
demonstrated 75.0% sensitivity and 85.7% specificity for
prediction of pCR (Table 2).
Analysis of mRNA expression according to preoperative
CRT responses
In  the  training  set,  the  mRNA expression  levels  of  the
studied biomarkers were not significantly different between
patients who did or did not develop T- or N-downstaging.
However, mRNAs of four biomarkers (p53, p21, Ki-67 and
CD133) were differentially expressed between patients who
had pCR and those who did not develop pCR, as well as
between  responders  to  CRT  (TRG  1−2)  and  non-
responders (TRG 3−4). Responders to CRT and patients
with pCR demonstrated significantly higher ΔCt and lower
2−ΔCt  of p53 mRNA, but lower ΔCt and higher 2−ΔCt  of
mRNA of p21, Ki-67, and CD133 (Table 3).
Logistic regression model for prediction of pCR
In univariate and multivariate logistic regression analyses of
the training set, tumor location, endoscopic findings, low
expression  of  p53  mRNA,  and  high  expression  of  p21,
Ki67,  CD133 mRNA were significantly  associated with
pCR (Table 4). These variables were selected for further
analysis as possible predictors of pCR to CRT.
Using logistic regression analysis, prediction models for
pCR  were  suggested  based  on  these  six  clinical  and
biological  variables (Table 5).  The mRNA expression of
each biomarker  was  presented as  a  ΔCt value.  Of three
prediction  models,  model  3  with  all  six  variables
demonstrated the highest AUC. The Hosmer-Lemeshow
goodness of fit test was not significant (P=0.984), indicating
good fit of this model.
Nomogram for prediction of pCR
The prediction model including p53, p21, Ki67, CD133,
endoscopy and tumor location to predict the probability of
pCR was visually represented by a nomogram (Figure 2).
From each variable’s value, a vertical line can be drawn to
the top point row and points for each variable are assigned.
The sum of each variable’s value indicates the total points.
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A vertical line is drawn downward from the total points row
to  obtain  the  probability  of  pCR.  According  to  the
nomogram, patients with total points of 210, 240 and 270
had estimated pCR probability  of  10%,  50% and 90%,
respectively. Figure 3A,B demonstrate the ROC curve and
calibration plot of the nomogram in the training set. Area
under the ROC curve of the multivariate model was 0.945
[95% confidence  interval  (95% CI):  0.900−0.989]  with
good  significance.  The  calibration  plot  showed  good





Training set (n=80) Validation set (n=40)
Age [median (range)] (year) 60 (36−86) 64 (37−86) 0.497
Sex 0.791
　Male 50 (62.5) 24 (60.0)
　Female 30 (37.5) 16 (40.0)
BMI [median (range)] (kg/m2) 23.4 (17.6−33.3) 23.0 (17.6−30.5) 0.473
Distance from AV [median (range)] (cm) 5.3 (1−11) 5.3 (1−10) 0.923
Tumor location 0.895
　Middle 31 (38.8) 16 (40.0)
　Low 49 (61.3) 24 (60.0)
Pre CRT CEA [median (range)] (ng/mL) 8.3 (0.5−51.8) 8.1 (0.9−46.2) 0.944
Pre CRT tumor volume [median (range)] (mL) 19.3 (2−82) 19.8 (2−53) 0.896
Initial tumor differentiation 0.576
　G1/G2 13 (16.3)/60 (75.0) 4 (10.0)/31 (77.5)
　G3/G4 6 (7.5)/1 (1.3) 5 (12.5)/0 (0)
Clinical T and N stages 0.846
　cT2N+ 2 (2.5) 1 (2.5)
　cT3N−/N+ 14 (17.5)/54 (67.5) 10 (25.0)/25 (62.5)
　cT4N−/N+ 1 (1.3)/9 (11.2) 0 (0)/4 (10.0)
Endoscopy 0.781
　cCR 26 (32.5) 12 (30.0)
　non-cCR 54 (67.5) 28 (70.0)
Pathological T and N stages 0.960
　ypT0N− 24 (30.0) 11 (27.5)
　ypT1N−/N+ 6 (7.5)/1 (1.3) 2 (5.0)/0 (0)
　ypT2N−/N+ 12 (15.0)/3 (3.8) 8 (20.0)/1 (2.5)
　ypT3N−/N+ 16 (20.0)/16 (20.0) 7 (17.5)/9 (22.5)
　ypT4N+ 2 (2.5) 2 (5.0)
TRG 0.987
　TRG 1/TRG 2 24 (30.0)/16 (20.0) 11 (27.5)/9 (22.5)
　TRG 3/TRG 4 28 (35.0)/12 (15.0) 14 (35.0)/6 (15.0)
Operation 0.955
　Low anterior resection 56 (70.0) 29 (72.5)
　uLAR with CAA 20 (25.0) 9 (22.5)
　APR 4 (5.0) 2 (5.0)
BMI, body mass index; AV, anal verge; CRT, chemoradiotherapy; CEA, carcinoembryonic antigen; G1, well differentiated; G2,
moderately differentiated; G3, poorly differentiated; G4, undifferentiated; cCR, clinical complete response; TRG, tumor regression
grade; uLAR, ultra-low anterior resection; CAA, coloanal anastomosis; APR, abdominal-perineal resection.
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external  validation  set,  the  AUC  was  0.922  (95%  CI:
0.841−0.999) with good significance. The calibration plot
of predicted and actual probability showed good correlation
in low and high probability areas. However, it appeared to
have  poor  correlation  in  the  middle  probability  area
because the intermediate probability could be ambiguous
for binary variables (Figure 3C,D).
Discussion
After  preoperative  CRT,  various  tumor  responses  are
presented  from  complete  remission  to  still  remaining
tumors. Complete remission is shown in about 10%−30%
of patients, and 60% show a partial tumor response and T
and N downstaging, although some tumors show a poor
response and no downstaging. If CR can be predicted, less
invasive surgery or close follow-up may be considered to
avoid radical resection in some cases (13).
Numbers of diagnostic tools have been investigated and
proposed for  assessment and prediction of  responses  to
CRT.  For  gross  evaluation  of  tumor  response  after
preoperative CRT, endoscopy, MRI and positron emission
tomography  (PET)  have  been  invest igated  and
demonstrated variable results. Furthermore, numbers of
molecular markers have been studied for assessment and
prediction of tumor response to preoperative CRT in rectal
Table 2 Univariate analysis of clinical variables associated with pCR and TRG in training set (n=80)
Characteristics
pCR [n (%)] TRG [n (%)]
Yes (n=24) No (n=56) P TRG 1−2 (n=40) TRG 3−4 (n=40) P
Age (year) 0.494 0.179
　≤60 14 (33.3) 28 (66.7) 18 (42.9) 24 (57.1)
　>60 10 (26.3) 28 (73.7) 22 (57.9) 16 (42.1)
Sex 0.313 1.000
　Male 13 (26.0) 37 (74.0) 25 (50.0) 25 (50.0)
　Female 11 (36.7) 19 (63.3) 15 (50.0) 15 (50.0)
BMI [median (range)] (kg/m2) 23 (18−30) 23 (17−33) 0.969 23 (18−30) 23 (17−33) 0.748
Tumor location (cm) 0.031 0.039
　Low (1−5) 19 (38.8) 30 (61.2) 29 (59.2) 20 (40.8)
　Middle (>5) 5 (16.1) 26 (83.9) 11 (35.5) 20 (64.5)
Pre CRT CEA (ng/mL) 0.249 0.251
　≤5 17 (34.7) 32 (65.3) 27 (55.1) 22 (44.9)
　>5 7 (22.6) 24 (77.4) 13 (41.9) 18 (58.1)
Pre CRT tumor volume
[median (range)] (mL) 16.1 (2−42) 21.0 (2−82) 0.227 16.5 (2−53) 22.7 (4−82) 0.100
Clinical T stage 0.477 0.176
　cT2/cT3 20 (28.6) 50 (71.4) 33 (47.1) 37 (52.9)
　cT4 4 (40.0) 6 (60.0) 7 (70.0) 3 (30.0)
Clinical N stage 0.363 0.775
　cN(−) 6 (40.0) 9 (60.0) 8 (53.3) 7 (46.7)
　cN(+) 18 (27.7) 47 (72.3) 32 (49.2) 33 (50.8)
Histology 1.000 1.000
　G1/G2 22 (30.1) 51 (69.9) 37 (50.7) 36 (49.3)
　G3/G4 2 (28.6) 5 (71.4) 3 (42.9) 4 (57.1)
Endoscopy <0.001 <0.001
　cCR 18 (69.2) 8 (30.8) 23 (88.5) 3 (11.5)
　Non-cCR 6 (11.1) 48 (88.9) 17 (31.5) 37 (68.5)
pCR, pathologic complete response; TRG, tumor regression grade; BMI,  body mass index;  CRT, chemoradiotherapy;  CEA,
carcinoembryonic antigen; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; G4, undifferentiated;
cCR, clinical complete response.
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OR 95% CI P OR 95% CI P
Age (year) 0.99 (0.95−1.03) 0.722
Sex 1.65 (0.62−4.37) 0.315
BMI (kg/m2) 1.00 (0.86−1.17) 0.967
AV distance (cm) 0.80 (0.64−1.02) 0.070
Tumor location 0.30 (0.10−0.93) 0.036 0.09 (0.01−0.94) 0.042
Pre CRT CEA (ng/mL) 0.99 (0.95−1.04) 0.816
Clinical T stage 0.39 (0.02−6.52) 0.511
Clinical N stage 0.57 (0.18−1.85) 0.352
Histology grade 1.55 (0.38−6.27) 0.543
Endoscopy 18.0   (5.48−59.11) 0.000 34.68   (7.62−78.64) 0.001
p53 ΔCt 1.71 (1.15−2.56) 0.008 2.19 (1.78−6.19) 0.039
p53 2−ΔCt 0.55 (0.33−0.91) 0.021 0.97 (0.21−4.56) 0.071
p21 ΔCt 0.60 (0.40−0.89) 0.010 0.77 (0.21−0.96) 0.045
p21 2−ΔCt 2.28 (1.28−4.06) 0.005 3.75 (1.50−8.28) 0.020
Ki67 ΔCt 0.66 (0.48−0.89) 0.008 0.38 (0.13−0.97) 0.042
Ki67 2−ΔCt 1.92 (1.25−2.96) 0.003 1.39 (1.09−1.81) 0.023
VEGF ΔCt 0.87 (0.68−1.12) 0.270
VEGF 2−ΔCt 1.04 (0.94−1.16) 0.406
CD133 ΔCt 0.63 (0.45−0.88) 0.007 0.39 (0.40−0.95) 0.040
CD133 2−ΔCt 1.63 (1.18−2.28) 0.003 1.28 (1.10−3.80) 0.035
CD24 ΔCt 0.99 (0.68−1.45) 0.972
CD24 2−ΔCt 1.01 (0.76−1.34) 0.959
CD44 ΔCt 1.08 (0.78−1.49) 0.656
CD44 2−ΔCt 1.19 (0.62−2.31) 0.600
RT-PCR, reverse transcriptase polymerase chain reaction; pCR, pathologic complete response; BMI, body mass index; AV, anal
verge; CRT, chemoradiotherapy; CEA, carcinoembryonic antigen; VEGF, vascular endothelial growth factor; OR, odds ratio; 95% CI,
95% confidence interval.
Table 5 Logistic regression model using biomarker expression in tumor tissue by RT-PCR and endoscopic findings for assessment of pCR
in training set (n=80)
Variable
Model 1 Model 2 Model 3
OR Lower Upper P OR Lower Upper P OR Lower Upper P
p53 ΔCt 1.948 1.212 3.547 0.013 2.101 1.186 3.722 0.011 1.717 1.039 3.263   0.053
p21 ΔCt 0.537 0.312 0.848 0.014 0.518 0.307 0.874 0.014 0.439 0.193 0.799   0.019
Ki67 ΔCt 0.671 0.434 0.905 0.034 0.726 0.512 1.030   0.073 0.642 0.384 0.900   0.027
CD133 ΔCt 0.799 0.51 1.197 0.296 0.787 0.515 1.202 0.268 0.594 0.318 1.002   0.069
Endoscopy − − − − − − − − 39.228   6.989 399.305     <0.000
Tumor
location − − − − 0.314 0.074 1.337 0.117 0.356 0.047 2.063   0.271
AUC 0.859 − − − 0.876 − − − 0.945 − − −
RT-PCR, reverse transcriptase polymerase chain reaction; pCR, pathologic complete response; AUC, area under the curver; OR,
odds ratio.
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cancer.  However,  the evidence is  insufficient,  and these
potential  predictive  markers  cannot  be  used  in  clinical
practice. Numbers of candidates still remain a hope for the
future.
In  the  present  study,  we  developed  a  nomogram
combining endoscopic findings of morphometric tumor
changes and mRNA expression levels of four biomarkers
(p53, p21, Ki67 and CD133) by quantitative RT-PCR to
predict pCR in rectal cancer patients receiving preoperative
CRT. This predictive model was externally validated and
showed  good  performance  in  terms  of  calibration  and
discrimination.  We  believe  that  this  comprehensive
nomogram is useful for pCR prediction and could provide
guidance for individualized treatment.
Previously, we reported a scoring system that used the
levels of expression of p53, VEGF, p21 and Ki67 measured
by IHC analysis (8). These proteins were chosen from a
panel  of  12  markers  as  having  a  significant  correlation
between expression level and pCR in 81 patients. Although
this technique is widespread and easily available, real-time
RT-PCR is  known as  a  more reliable  and reproducible
method that allows quantification of gene expression (14).
Therefore,  we  evaluated  mRNA  expression  levels  of  7
candidate biomarkers and 4 biomarkers (p53, p21, Ki67 and
CD133) showed the significant correlation with pCR (8).
In this study, we added endoscopic findings as a clinical
tool for evaluation of morphometric changes of the tumor
after preoperative CRT. The classification according to
morphologic characteristics should be generalized in large-
scale series. However, gross tumor response findings would
be  valuable  assessment  modalities  for  prediction  of
pathologic tumor response. In our study, we demonstrated
the importance of endoscopic evaluation of primary tumor
after  preoperative CRT for rectal  cancer.  Although the
number  of  patients  studied  is  rather  small,  one  of  the
strengths of this study is its prospective nature. In contrast
to our previous study, all consecutive patients in the study
period were included, thus overcoming the influence of
selection bias inherent in retrospective studies.
In  addition  to  p53,  VEGF,  p21  and  Ki67  from  our
previous study (8), three cancer stem cell proteins (CD133,
CD24,  CD44)  were  selected  as  potential  candidate
biomarkers.
Among  the  significant  biomarkers  identified  in  the
present  study,  tumor  protein  p53  is  probably  the  most
extensively studied biomarker in this field, and a number of
studies  have  shown  that  the  presence  of  p53  mutation
correlates inversely with pCR, although this association was
not significant in all studies (8,15-17). The results of our
present  investigation  confirm  the  findings  from  our
previous research (8) and other research groups (16,17) that
low  expression  of  mutant  p53  is  predictive  of  tumor
response to CRT and pCR.
The biomarkers p21 and Ki67 are related to inhibition of
the cell cycle and high proliferative activity of tumor cells,
respectively. However, their clinical significance in rectal
cancer  is  still  unclear  as  controversial  data  have  been
reported to date (18-23). Our present work is consistent
with  our  previous  IHC  study  and  showed  that  high
expression of p21 and Ki67 is strongly associated with pCR.
Cancer stem cells show the resistance to chemotherapy
and  radiotherapy.  CD133,  CD44,  and  CD24  are  well-
known colorectal  cancer  stem cell  markers.  Therefore,
these cancer stem cell markers have been investigated to
determine the correlation with the treatment response to
CRT  in  patients  with  rectal  cancer  (24-31).  CD133
expression indicates the existence of cancer stem cells, and
Sprenger  et  al.  reported that  a  high expression level  of
CD133 in rectal cancers treated with preoperative CRT
demonstrated  a  high  recurrence  rate  and  poor  survival
outcomes (32). Another stem cell marker CD24 was also
reported to be related with invasiveness and differentiation
in  colorectal  cancer  (26).  Huh  et  al.  investigated  13
molecular markers and only highly measured CD44 mRNA
level in pretreatment biopsies was significantly associated
with poor tumor response after CRT. Otherwise, CD133
and other stem cell markers demonstrated no significant
association with tumor response (24). In contrast, in our
 
Figure  2  Nomogram  predicting  probability  of  pCR  after
preoperative chemoradiotherapy in rectal cancer. The nomogram
is used by totaling the points identified on the top scale for each of
six  independent  variables.  The  total  points  projected  to  the
bottom scale indicate the % probability of pCR. pCR, pathologic
complete remission; cCR, clinical complete remission.
236 Hur et al. Prediction nomogram of chemoradiotherapy
© Chinese Journal of Cancer Research. All rights reserved. www.cjcrcn.org Chin J Cancer Res 2020;32(2):228-241
study, high expression of CD133 mRNA was associated
with  better  response  to  CRT  and  higher  pCR  rate.
Currently, the association between colorectal cancer stem
cell markers and CRT response is not firmly established.
Numbers of studies presented the possibility and need for
further investigation.
In  this  study,  endoscopic  findings  after  preoperative
CRT were  significantly  correlated  with  the  pathologic
tumor response. However, endoscopic findings alone lead
to false positive and negative predictions. In the total set of
120 patients, 26 (68.4%) of 38 patients with endoscopic CR
showed pCR, and 12 (31.6%) patients showed non-pCR.
Of 35 patients showing pCR in 120 patients, 26 (74.3%)
patients were endoscopic CR and 9 (25.7%) patients were
not CR. More comprehensive approach with various tools
is  needed  to  improve  the  accuracy  of  tumor  response
prediction.  The  endoscopic  and  pathologic  CR  group
showed  a  lower  p53  and  higher  p21,  Ki67,  CD133
expression than the endoscopic CR and non-pCR group.
Of 82 patients with endoscopic non-CR, nine showed pCR,
and 73 showed non-pCR. The endoscopic and pathologic
non-CR group showed higher p53 and lower p21, Ki67,
CD133 expression than the endoscopic non-CR and pCR
group (Table 6). Therefore, the endoscopic findings could
 
Figure 3 Discrimination and calibration of a nomogram in training set (n=80) and external validation set (n=40). (A) Receiver operating
characteristic (ROC) curve by the multiple logistic model in the training set. Area under the ROC curve (AUC) is 0.945 [95% confidence
interval (95% CI): 0.900−0.989); (B) Calibration plot for probability of pathologic complete remission (pCR) in the training set. Predicted
and actual pCR probabilities are plotted as logistic calibration (bootstrap 300 repetitions); (C) ROC curve by multiple logistic models in the
external validation set. AUC is 0.922 (95% CI: 0.841−0.999); (D) Calibration plot for probability of pCR in the external validation set.
Predicted and actual pCR probabilities are plotted as logistic calibration (bootstrap 300 repetitions).
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be complemented by inclusion of biomarker expression to
reduce false results.
To date, various models or nomograms for prediction of
CRT response in  patients  with rectal  cancer  have been
presented from several studies (33-35). Van stiphout et al.
(36) suggested a nomogram predicting pCR after CRT for
locally advanced rectal cancer using clinical features and
early  sequential  18F-FDG PET-CT imaging.  The pCR
rate was 21.4% in the training set (n=112) and 23.1% in the
validation set (n=78). The nomogram was presented based
on the selected predictive values including cT-stage, cN-
stage,  response index of  SUVmean,  and maximum tumor
diameter during treatment.  The AUC was calculated to
evaluate  the  model  performance.  AUC  were  0.78  in
training group and 0.70 in validation group. According to
the measured probabilities for pCR, several groups were
assigned. The high probability group demonstrated correct
predictions for pCR in 100% for the training set and 67%
for validation sets, respectively.
Jwa et al.  (37) investigated clinical features correlated
with ypN status after preoperative CRT in rectal cancer.
Patient age,  tumor differentiation,  cN stage,  ypT stage,
lymphovascular  invasion,  and  perineural  invasion  were
significantly associated with LN status after CRT. These
clinical values were used for development of the nomogram
for prediction of ypN status in a training cohort (n=891). A
separate  cohort  (n=258)  was  used  for  validation  of  the
established  nomogram.  The  nomogram  showed  good
discrimination ability in training and validation cohorts.
The  calibration  plot  demonstrated  good  agreement
between actual and predicted LN status after preoperative
CRT.
Nomograms for prediction of treatment response have
also been investigated in breast cancer (38-40). Keam et al.
(40) combined clinical pathologic variables of 370 breast
cancer  patients  that  are  associated  with  pCR  after
neoadjuvant chemotherapy into a prediction nomogram.
Clinical  variables  included  initial  tumor  size,  estrogen
receptor, human epidermal growth factor receptor 2 and
Ki67.  The  nomogram  based  on  these  variables
demonstrated  good  discrimination  performance
(AUC=0.830).  The  agreement  between  predicted  and
observed outcomes was good in the low probability area of
calibration plot. However, in the high probability area, the
predicted  probability  of  pCR  did  not  show  a  good
agreement  with  the  observed  probability  of  pCR.  This
result may be from the relatively low pCR rate (32 of 370
patients, 8.6%).
Our  prediction  nomogram  demonstrated  good
performance of discrimination and calibration abilities in
the  training  set.  However,  despite  good discrimination
ability in the validation set,  the calibration plot did not
show perfect agreement; there was good correlation in low
and  high  probability  of  pCR  but  not  in  the  middle
probability area. If the tumor response is definitely good or
bad  (TRG  1  or  TRG  4),  the  actual  and  predicted
probability will be correlated well and calibration results is
good.  But,  moderate  tumor  response  (TRG  2  or  3)
compared  with  definitely  good  or  bad  (TRG  1  or  4)
response may be not correlated well and calibration results
are  poor.  This  indicates  the  need  for  a  more  reliable
prediction model for those with intermediate scores.
Endoscopic morphometric change is  easily accessible,
and the  RT-PCR approach is  less  time consuming and
more reliable than IHC analysis.  Our prediction model
demonstrated high discrimination and calibration abilities
in identifying patients who are likely to develop pCR and
thus have a favorable predicted outcome and might be able





value pCR P53 P P21 P Ki67 P CD133 P
CR (n=38) ΔCt ( ) Yes (n=26) 6.66±1.17 0.235 5.54±1.67 0.131   7.95±1.49   0.111 8.29±1.96   0.599
No (n=12) 6.16±1.28 6.49±1.98 10.08±4.16 8.54±0.86
2−ΔCt ( ) Yes (n=26) 1.17±0.77 0.175 2.06±2.49 0.154   1.41±1.27   0.445 1.90±1.79   0.039
No (n=12) 1.81±1.44 0.99±0.78   1.07±1.31 1.03±0.72
Non-CR
(n=82)
ΔCt ( ) Yes (n=9) 6.41±2.19 0.562 5.30±1.59 0.010   6.84±0.72 <0.001 6.49±0.43 <0.001
No (n=73) 5.96±1.17 6.45±1.20 10.08±3.82 9.11±1.97
2−ΔCt ( ) Yes (n=9) 1.93±1.35 0.995 1.99±1.42 0.036   2.19±1.17 <0.001 3.66±0.90 <0.001
No (n=73) 1.93±1.37 0.80±0.61   0.81±0.90 1.18±1.47
pCR, pathologic complete remission; CR, complete remission.
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to avoid major surgery. However, this was a monocentric
study, before implementation of this prediction model in
practice, it should be tested and validated on another large
independent patient cohort from multi-centers. This study
is planned as the next step in our work.
Conclusions
The  present  research  demonstrated  the  benefit  of  the
developed model in prediction of pCR after preoperative
CRT  in  patients  with  rectal  cancer.  Our  prediction
nomogram encompassed  clinical  and  biological  factors
including tumor location, endoscopic findings, and four
biomarkers  and achieved  high sensitivity  and sufficient
accuracy in prediction of pCR. This finding suggests that
cancer sensitivity to CRT should be evaluated as a complex
system,  rather  than  as  separate  processes.  We  used  a
combination of biomarkers and morphometric endoscopic
findings that showed distinct patterns of expression and
features  between  pCR  and  non-pCR  and  developed  a
prediction  nomogram.  Despite  certain  limitations,  this
study demonstrated the importance of a multidirectional
approach and the  utility  of  a  prediction  nomogram for
identifying patients likely to show pCR and development of
treatment strategies.
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